Close Menu

NEW YORK (GenomeWeb) – A subset of solid tumors containing PDL1 amplifications appear more prone to respond to immune checkpoint blockade immunotherapy, even in the absence of high PD-L1 protein expression, microsatellite instability (MSI), or enhanced tumor mutational burden (TMB).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.


This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.